Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
SAN CARLOS, Calif., Sept. 18, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society for Medical…
Comments Off on Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting